<DOC>
	<DOCNO>NCT00977106</DOCNO>
	<brief_summary>This study ass onset maintenance effect tocilizumab relief patient active moderate severe rheumatoid arthritis inadequate response DMARDs anti-TNF . For first , double-blind , part study patient randomize receive iv infusion either 8mg/kg tocilizumab placebo . After 4 week follow 11 month treatment tocilizumab 8mg/kg iv infusion every 4 week . Methotrexate DMARD therapy continue throughout study treatment . Target sample size &gt; 100 .</brief_summary>
	<brief_title>TORPEDO Study : A Study Rapid Effect Tocilizumab Patients With Rheumatoid Arthritis With Inadequate Response Disease-Modifying Antirheumatic Drugs ( DMARDs ) Anti-TNF</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient &gt; /= 18 year age active moderate severe rheumatoid arthritis &lt; 10 year duration inadequate response methotrexate antiTNF methotrexate treatment least 10 week , least 8 week stable dose patient receive oral corticosteroid and/or NSAIDs stable dose 4 week rheumatic autoimmune disease RA , significant systemic involvement secondary RA functional class IV ACR classification history inflammatory joint disease RA previous treatment celldepleting therapy , abatacept rituximab active current history recurrent infection , major episode infection require hospitalization treatment iv antibiotic &lt; 4 week oral antibiotic &lt; 2 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>